Vir Biotechnology (NYSE:VIR) Major Shareholder Acquires $13,509,000.00 in Stock

Vir Biotechnology (NYSE:VIR) major shareholder Endurance (Cayman) Ltd Svf purchased 950,000 shares of the firm’s stock in a transaction on Wednesday, October 16th. The stock was acquired at an average price of $14.22 per share, for a total transaction of $13,509,000.00. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

VIR opened at $13.66 on Friday. Vir Biotechnology has a 1-year low of $13.39 and a 1-year high of $16.50.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, a clinical-stage immunology company, develops therapeutic products for the treatment and prevention of serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus, and VIR-2020 for the prevention of tuberculosis.

Recommended Story: Does the Dogs of the Dow strategy work?

Leave a Reply

Your email address will not be published. Required fields are marked *